Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
- PMID: 8839835
Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells
Abstract
Proteinase 3 is present in high concentration in the primary granules of acute and chronic myeloid leukemia blasts, and may represent a potential T-cell target antigen. We screened proteinase 3 against the binding motif of HLA-A2.1. Based on its high predicted binding, a 9-mer peptide, "PR-1," was synthesized and tested for binding to HLA-A2.1 using the T2 cell line. PR-1 at 100 micrograms/mL significantly increased expression of HLA-A2.1, with median channel of fluorescence increasing from 22 to 294. Binding half-life was determined to be 1,460 minutes by I125-labeled beta 2-microglobulin incorporation. HLA-A2.1+ peripheral blood mononuclear cells from a normal donor were used to generate a T-cell line specific for PR-1. The line demonstrated 85% PR-1-specific lysis at an E:T ratio of 50:1, compared with 20% lysis without PR-1, using T2 cells as targets. It also showed 79% specific lysis to fresh chronic myelogenous leukemia blasts, 54% to fresh acute myelogenous leukemia blasts, and only background lysis (< 20%) to HLA-A2.1+ normal allogeneic marrow cells. The amount of lysis of HLA-A2.1+ myeloid cells was proportional to cytoplasmic proteinase 3 expression. Thus, HLA-A2.1-restricted cytotoxic T cells, raised against a peptide contained in proteinase 3, preferentially lysed fresh human leukemic cells.
Similar articles
-
PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007. Cytotherapy. 2016. PMID: 27378343 Free PMC article.
-
Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units.Blood. 1997 Oct 1;90(7):2529-34. Blood. 1997. PMID: 9326217
-
A PR1-human leukocyte antigen-A2 tetramer can be used to isolate low-frequency cytotoxic T lymphocytes from healthy donors that selectively lyse chronic myelogenous leukemia.Cancer Res. 1999 Jun 1;59(11):2675-81. Cancer Res. 1999. PMID: 10363991
-
Allorestricted cytotoxic T cells specific for human CD45 show potent antileukemic activity.Blood. 2003 Feb 1;101(3):1007-14. doi: 10.1182/blood-2002-02-0525. Epub 2002 Sep 12. Blood. 2003. PMID: 12393606
-
Antitumor cytotoxic T-lymphocyte response in human lung carcinoma: identification of a tumor-associated antigen.Immunol Rev. 2002 Oct;188:114-21. doi: 10.1034/j.1600-065x.2002.18810.x. Immunol Rev. 2002. PMID: 12445285 Review.
Cited by
-
Neutrophil elastase enhances antigen presentation by upregulating human leukocyte antigen class I expression on tumor cells.Cancer Immunol Immunother. 2016 Jun;65(6):741-51. doi: 10.1007/s00262-016-1841-6. Epub 2016 Apr 29. Cancer Immunol Immunother. 2016. PMID: 27129972 Free PMC article.
-
Activity of 8F4, a T-cell receptor-like anti-PR1/HLA-A2 antibody, against primary human AML in vivo.Leukemia. 2016 Jul;30(7):1475-84. doi: 10.1038/leu.2016.57. Epub 2016 Mar 8. Leukemia. 2016. PMID: 27055866 Free PMC article.
-
A novel TCR-like CAR with specificity for PR1/HLA-A2 effectively targets myeloid leukemia in vitro when expressed in human adult peripheral blood and cord blood T cells.Cytotherapy. 2016 Aug;18(8):985-994. doi: 10.1016/j.jcyt.2016.05.001. Epub 2016 Jun 2. Cytotherapy. 2016. PMID: 27265873 Free PMC article.
-
PR1-specific cytotoxic T lymphocytes are relatively frequent in umbilical cord blood and can be effectively expanded to target myeloid leukemia.Cytotherapy. 2016 Aug;18(8):995-1001. doi: 10.1016/j.jcyt.2016.05.007. Cytotherapy. 2016. PMID: 27378343 Free PMC article.
-
A novel HLA-A*0201 restricted peptide derived from cathepsin G is an effective immunotherapeutic target in acute myeloid leukemia.Clin Cancer Res. 2013 Jan 1;19(1):247-57. doi: 10.1158/1078-0432.CCR-12-2753. Epub 2012 Nov 12. Clin Cancer Res. 2013. PMID: 23147993 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous